NCT00830245View on ClinicalTrials.gov

A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Leptomeningeal CarcinomatosisNon-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

Erlotinib 150mg/day

Trial Locations (1)

Unknown

Dae Seog Heo, Seoul

Sponsors
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Korean Cancer Study Group

OTHER

lead

Clinical Research Center for Solid Tumor, Korea

OTHER